Breast Cancer :: Abortion pill offers hope for breast cancer patients
A new research study published in Science revealed that abortion pill Mifeprex, Mifepristone or RU-486 offers hope for breast cancer patients.
Breast cancer
Breast Cancer :: Combination therapy shows improvement for breast cancer patients
Giving radiation therapy and chemotherapy at the same time after a lumpectomy helps keep breast cancer from returning locally, according to a study published in the Dec. 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.
Breast Cancer :: Abortion pill Mifeprex, RU-486 blocks breast cancer
Cell biologist Eva Lee of the University of California, Irvine, who led the research published in Friday’s edition of the journal Science, reported that a pill that women can take to abort a fetus, has the ability to put a strangle hold on the gene primarily responsible for breast cancer. The drug is called RU-486, and when given to genetically developed mice who were destined to develop breast cancer, proved to halt the progression of the disease.
Breast Cancer :: Cancer prognosis gene GATA-3 found to control the fate of breast cells
Scientists have discovered an unsuspected role for a gene known to be one of the best predictors of human breast cancer outcome.
Breast Cancer :: Second opinion yields treatment changes for half of patients
More than half of breast cancer patients who sought a second opinion from a multidisciplinary tumor board received a change in their recommended treatment plan, according to a new study from the University of Michigan Comprehensive Cancer Center.
Breast Cancer :: Aeterna Zentaris – Positive Top Line Phase 1 Results for AN-152 in Gynaecological and Breast Cancers
?terna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today disclosed additional positive top line Phase 1 results for its cytotoxic conjugate AN-152 in patients with gynaecological and breast cancers. Further data showed the compound?s good safety profile and established the maximum tolerated dose (MTD) at 267 mg/m? which will be the recommended dose for a Phase 2 trial. In addition to good safety data, the trial provided a hint of efficacy as disease stabilization and regression of lesions were observed at the 160 mg/m? and 267 mg/m? dose levels.
Breast Cancer :: Big bias in who gets screened for breast cancer
Certain women may miss out on routine tests that screen for early signs of breast cancer. Elderly women, women with publicly funded health insurance and women who don’t go to an obstetrician and gynecologist for routine exams are all less likely than others to get a clinical breast exam and a recommendation for a mammogram.
Breast Cancer :: Quest for better breast cancer drugs
Breast cancer sufferers could eventually benefit from high-tuned, tailor-made drug treatments that minimize side effects as a result of a joint initiative between computer scientists in Edinburgh and cellular biologists in Japan.
Breast Cancer :: Fresh use of targeted therapy advances treatment of early HER2-positive breast cancer
The news that the world’s first targeted therapy, trastuzumab (Herceptin), is now available for many women with early-stage HER2-positive breast cancer “highlights a truly significant advance in the management of breast cancer,” says Edith Perez, M.D., director of Mayo Clinic’s Breast Clinic in Jacksonville, Fla.
Breast Cancer :: FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy
The U. S. Food and Drug Administration (FDA) today expanded the approved use of Herceptin, a biological cancer drug. The new indication is for Herceptin, in combination with other cancer drugs, for the treatment of HER2 positive breast cancer after surgery (lumpectomy or mastectomy). FDA granted priority review to the supplemental application for Herceptin.